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background: Ovarian hormones, parity and length of ‘menarche-to-ﬁrst birth’ time interval are known risk factors for breast cancer,
yet the associations between 17b-estradiol, progesterone and these reproductive factors remain unclear.
methods: A total of 204 women (25–35 years) who participated in the Norwegian EBBA-I study collected daily saliva samples for one
complete menstrual cycle, and ﬁlled in a reproductive history questionnaire. Anthropometry was measured and saliva samples were analyzed
for ovarian hormones. Associations between parity, the interval and ovarian hormones, and effects of hormone-related lifestyle factors were
studied in linear regression models.
results: Mean age was 30.7 years, and age of menarche 13.1 years. Parous women had on average 1.9 births, and age at ﬁrst birth was
24.5 years. No association was observed between parity and ovarian steroids. In nulliparous women, higher waist circumference
(≥77.75 cm) and longer oral contraceptive (OC) use (≥3 years) were associated with higher levels of 17b-estradiol. Short (,10 years)
versus long (.13.5 years) ‘menarche-to-ﬁrst birth’ interval was associated with higher overall mean (Ptrend ¼ 0.029), 47% higher
maximum peak and 30% higher mid-cycle levels of 17b-estradiol. We observed a 2.6% decrease in overall mean salivary 17b-estradiol
with each 1-year increase in the interval.
conclusions: Nulliparous women may be more susceptible to lifestyle factors, abdominal overweight and past OC use, inﬂuencing
metabolic and hormonal proﬁles and thus breast cancer risk. Short time between ‘menarche-to-ﬁrst birth’ is linked to higher ovarian
hormone levels among regularly cycling women, suggesting that timing of ﬁrst birth is related to fecundity.
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Introduction
Ovarianfunctionplaysafundamentalroleinfemalefecundityandfertility
(Lipson and Ellison, 1996), and ovarian hormones are major risk factors
for breastcancer initiation and progression (Jasienska and Thune, 2001;
Endogenous Hormones and Breast Cancer Collaborative Group, 2002;
Eliassen et al., 2006; McTiernan et al., 2006). Furthermore, it is well
established that early age at menarche, late age at ﬁrst birth and low
parityincreasesbreastcancerrisk,anditisgenerallythoughtthatrepro-
ductive events and their timing mayinﬂuence breast cancer risk through
their effects on differentiation of breast tissue and on hormonal and
immunological proﬁles (Verkasalo et al., 2001; Ma et al., 2006; Li
et al., 2008). Given the large changes in both the timing of sexual matu-
ration and childbearing pattern, and the rise in breast cancer incidence
worldwide (Kaplowitz, 2006; World Cancer Research Fund/American
Institute for Cancer Research, 2007), deﬁning the relationship between
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is of particular importance.
Younger age at menarche is associated with higher cumulative
exposure to ovarian hormones throughout life (Apter et al., 1989;
Bernstein et al., 1991; Emaus et al., 2008a). Both early age at
menarche and delayed ﬁrst full-term birth translate into a longer
‘menarche-to-ﬁrst birth’ time interval, which is recognized as a suscep-
tible period for breast cancer development as the undifferentiated
breast tissue is exposed to mitogenic estrogen and progesterone
(Russo et al., 1982; Li et al., 2008). Moreover, overweight and
obesity are established risk factors for breast cancer among post-
menopausal women (Ballard Barbash et al., 2006), and girls with
excessive body fat tend to experience early age at menarche
(Emaus et al., 2008a) and reduced fecundity (Crosignani et al., 2003).
To our knowledge, data regarding levels of ovarian hormones
throughout a menstrual cycle in relation to parity and timing of ﬁrst
birth are very limited. Our previous studies show that 17b-estradiol
proﬁles are associated with age at menarche (Emaus et al., 2008a),
body composition from birth to adult life (Jasienska et al., 2006a;
Finstad et al., 2009a), metabolic proﬁle in adult life (Furberg et al.,
2005; Emaus et al., 2008b) and energy balance throughout the men-
strual cycle (Ziomkiewicz et al., 2008). These associations point to
further studies of ovarian hormones in relation to both fecundity
and fertility, and reproductive risk factors for breast cancer.
Thus, we chose to study the variation in the primary endogenous
ovarian hormones in premenopausal years, 17b-estradiol and pro-
gesterone. A unique aspect of this study is the daily assessments of
salivary 17b-estradiol and progesterone, which represent the free,
unbound, biologically active fraction of these hormones (Ellison and
Lipson, 1999). Therefore, the main aim of the present study was to
elucidate whether daily levels of free and biologically active
17b-estradiol and progesterone throughout an entire menstrual
cycle are associated with parity and the ‘menarche-to-ﬁrst birth’
time interval.
Materials and Methods
Participants and study design
In the Norwegian EBBA-I study (2000–2002), women aged 25–35 years
and living in the municipalities of Tromsø and Balsfjord were recruited by
local announcements in media and public meeting places (Furberg et al.,
2005). Among those who volunteered to participate, 214 women met the
inclusion criteria (age: 25–35 years, self-reported regular menstruation,
normal cycle length within the previous 3 months, no use of steroid contra-
ceptives,nopregnancyorlactationovertheprevious6months,nohistoryof
gynecological disorder and no chronic disorders, e.g. diabetes and hypo-/
hyperthyroidism). Suitable respondents were subsequently enrolled in the
study, and a total of 204 healthy women completed the study.
Questionnaires and interview
We used questionnaires to collect information including age at menarche,
reproductive history, marital status, education, physical activity, previous
use of hormonal contraceptives, smoking and alcohol consumption.
Data from a 7-day pre-coded food diary were used to estimate daily
energy intake (Furberg et al., 2005; Lillegaard et al., 2005). All question-
naires were checked for inconsistencies, and interview by one trained
nurse was performed. Recall and memory-probing aids including a lifetime
calendar and a list of examples of milestones, were used to date the repro-
ductive history events (Furberg et al., 2005; Emaus et al., 2008a).
Clinical parameters
All clinical procedures and measurements were conducted by trained
nurses at the Clinical Research Center, University Hospital of North
Norway (UNN), Tromsø. Each study participant came to the research
center three times for clinical examination: ﬁrst visit (Days 1–5 of the
menstrual cycle), second visit (Days 7–12) and third visit (Days 21–25).
The ﬁrst visit was conducted on the ﬁrst day possible after the onset of
menstrual bleeding. Anthropometric measurements were taken with par-
ticipants wearing light clothing and no footwear (Furberg et al., 2005;
Finstad et al., 2009b). Body height was measured to the nearest 0.5 cm,
and body weight to the nearest 0.1 kg on an electronic scale. BMI
(kg/m
2) was used to estimate relative weight. Waist circumference
(WC, cm) was measured in a horizontal line 2.5 cm above the umbilicus,
and hip circumference (HC, cm) was measured at the largest circumfer-
ence of the hip (Finstad et al., 2009a). WC and HC (measured to the
nearest 0.5 cm) were used to calculate Waist-to-Hip Ratio (WHR ¼
WC/HC). Blood pressure (BP) was measured three times (PROPAQ
104), with the participants sitting in a resting position, and the mean of
the ﬁnal two measurements was used in the analysis.
Saliva hormone samples and analysis
Women collected daily morning saliva samples at home for one entire
menstrual cycle starting on the ﬁrst day of bleeding. Previously established
collection protocols (Lipson and Ellison, 1996) were modiﬁed and devel-
oped for use (Furberg et al., 2005). Hormone assays were run in the
Reproductive Ecology Laboratory at Harvard University, USA.
In each cycle, 17b-estradiol was assayed for 20 days (reverse cycle days:
25t o224) and progesterone was assayed for 14 days (reverse cycle
days: 21t o214), and all values were used in calculation of overall
mean hormone concentrations for all participants. Salivary 17b-estradiol
and progesterone measurements were made using I-125 based radio-
immunoassay (RIA) kits (Diagnostic Systems Laboratories, Webster, TX,
USA) with published modiﬁcations to the manufacturer’s protocols
(Furberg et al., 2005). All samples were run in duplicate, and all samples
from an individual were run in the same assay, with women randomly
assigned to assays.
Saliva pools characterized by high or low hormone values (appropriate
to the range of each steroid) were run in each assay. The sensitivity of the
17b-estradiol assay (lowest value measurable by assay) was 4 pmol/l.
Average intra-assay variability was 9% and inter-assay variability ranged
from 23% for low pools to 13% for high pools. For progesterone, the sen-
sitivity of the assay was 13 pmol/l. Average intra-assay variability was 10%,
and inter-assay variability ranged from 19% for low pools to 12% for high
pools.
Before statistical analysis of daily hormonal levels, all cycles were aligned
at mid-cycle following published methods (Lipson and Ellison, 1996). Align-
ment was based on the identiﬁcation of the mid-cycle 17b-estradiol drop
(aligned cycle Day 0), which provides a reasonable estimate of the day of
ovulation. Identiﬁcation of the mid-cycle 17b-estradiol drop could not be
made for 14 women, and they were not included in subsequent analyses.
For the remaining 99 nulliparous and 91 parous women with aligned
cycles, the following follicular and luteal hormonal indices were calculated:
‘mid-follicular’ (deﬁned as the average of values for aligned cycle Days 210
to 26); ‘late-follicular’ (deﬁned as the average of values for aligned cycle
Days 25t o21); ‘luteal’ (deﬁned as the average of values for aligned
cycle Days +2t o+9); ‘mid-menstrual’ (deﬁned as the average of
values for aligned cycle Days 27t o+6); ‘mid-cycle’ (deﬁned as the
average of values for aligned cycle Days 24t o+2). Maximum peak
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menstrual index.
The 17b-estradiol levels in saliva represent the free, unbound, biologi-
cally active fraction of the circulating steroid only, rather than the levels
of both free and protein-bound 17b-estradiol as in serum [i.e. bound to
sex-hormone-binding globulin (SHBG) and albumin] (Ellison and Lipson,
1999). Furthermore, as saliva can readily be collected from individuals
on many occasions, it is possible to compare 17b-estradiol levels across
entire menstrual cycles among different women, rather than relying on
one or a few timed blood samples (Jasienska et al., 2006b).
Serum lipid samples and analysis
Fasting serum blood samples were drawn from an antecubital vein in the
morning on each of the three visits. Lipids were measured at the Depart-
ment of Clinical Chemistry, University Hospital of North Norway using
fresh sera from the ﬁrst visit (Furberg et al., 2005). Serum triglycerides
were assayed by enzymatic hydrolysis with lipase. Serum cholesterol was
determined enzymatically using cholesterol esterase and cholesterol
oxidase. High-density lipoprotein cholesterol (HDL-C) was quantiﬁed by
a direct assay using polyethylene glycol modiﬁed enzymes and dextran
sulfate.
Ethical considerations
All participating women signed an informed consent form, and the study
was approved by the Regional Committee for Medical Research Ethics
and the Norwegian Data Inspectorate.
Statistical analysis
We used multivariable linear regression models to study whether parity
and the timing of births in relation to age at menarche were associated
with levels of salivary 17b-estradiol and progesterone (STATA version
SE 11.0). All hormone data were log transformed prior to the linear
regression analyses: for presentation, all hormone values were trans-
formed back to the original scale (geometric Means and 95% Conﬁdence
Intervals).
To study the associations between parity and 17b-estradiol and pro-
gesterone, nulliparous women were compared with parous women and
potentially confounding factors were taken into account on the basis of
biological plausibility. Parity was included as a dichotomous (nulliparous
versus parous), and a continuous (number of full-term childbirths) predic-
tor variable in separate linear regression models. The following potentially
confounding factors were assessed on the basis of biological plausibility:
BMI, cycle length, age at menarche, smoking, alcohol, physical activity
and previous use of oral contraceptives (OCs). However, only minor
changes in the regression coefﬁcient of parity were observed for each of
these covariates in the models. Thus, age was the only covariate included
in the ﬁnal models. We elucidated possible effect modiﬁcation and
thresholds for variables of importance for the association between
parity and ovarian hormones. Thus, we stratiﬁed by number of children
(0, 1–2, ≥3), body composition: BMI (overweight, ≥25 kg/m
2) and
WC (Median, ≥77.75 cm), and previous OC use (Median ≥ 3 years).
Generalized estimating equation (GEE) regression models were used to
assess the association between daily salivary 17b-estradiol concentrations
and parity groups.
The parous women were further categorized into tertiles of the interval
between age at menarche and age at ﬁrst full-term birth: ,10 years, 10–
13.5 years and .13.5 years. The tertile groups were compared according
to characteristics associated with breast cancer risk and/or fecundity. The
‘menarche-to-ﬁrst birth’ time interval was included as a continuous and
categorical predictor in different regression models. The same potentially
confounding factors were evaluated as in the parity models, and only
minor changes in the regression coefﬁcient of the ‘menarche-to-ﬁrst
birth’ interval were observed. Thus, age was the only covariate
included in the ﬁnal models. Linear and logistic regression analyses were
used to assess linear trends over tertiles of the ‘menarche-to-ﬁrst birth’
interval.
To study whether variation in age at participation and BMI modiﬁed the
associations between ovarian hormones and the ‘menarche-to-ﬁrst birth’
interval (tertiles), age and BMI were dichotomized by median split
(33 years) and the cut off for overweight (≥25 kg/m
2), respectively. Poss-
ible two-way interactions between the ‘menarche-to-ﬁrst birth’ interval
and age, BMI, WC, and OC use were assessed in separate models. GEE
regression models were used to assess the associations between daily sali-
vary 17b-estradiol concentrations and groups of women in different
‘menarche-to-ﬁrst birth’ intervals.
Area under the curve (AUC) for the time–salivary hormone concen-
tration curves was calculated using the trapezium rule (Matthews et al.,
1990). Measurements of 17b-estradiol for the 14 mid-menstrual days
(aligned cycle Days 27t o+6), the 10 late follicular days (aligned
cycle Days 210 to 21), the 7 mid-cycle days (aligned cycle Day 24
to +2) and of progesterone for the 8 luteal days (aligned cycle Days
+2t o+9) were used in AUC calculations. Linear interpolation (i.e.
the mean of the days immediately prior and following) was used to
assign a value to days with missing values. If the missing value appeared
at the end of the interval, the value from the day next to the missing
value was used. One cycle for 17b-estradiol and two cycles for pro-
gesterone were excluded from calculations due to two or more
missing days at one of the ends of the interval. Among the 189
women included in the AUC analysis, the average number of missing
values per cycle was 0.6 days for 17b-estradiol in both parous and nul-
liparous women and 0.5 days (parous women) and 0.3 days (nulliparous
women) for progesterone; both hormones had a range of 0–4 missing
days per cycle. Linear regression was used to assess the differences in
AUC between parous groups and tertiles of the ‘menarche-to-ﬁrst
birth’ interval.
Results
Parity and hormonal levels
The average age of nulliparous women (n ¼ 106) was 29.2 years
(range: 25.0–35.3) and the average age of parous women (n ¼ 98)
was 32.4 years (range: 24.9–35.9). Mean reported age at menarche
was 13.2 years (range: 10.5–19.5) for nulliparous and 13.1 years
(range: 9.20–17.0) for parous women (Table I). Mean age at ﬁrst full-
term pregnancy was 24.5 years (range: 16.0–32.0), and parous
women had on average 1.9 children (range: 1–5). Compared with nul-
liparous women, parous women were older (P , 0.001), with a higher
BMI (P ¼ 0.012), larger WC (P , 0.001), lower HDL-C (P ¼ 0.049)
and had lower alcohol consumption (P , 0.001) (Table I).
There was no difference in overall mean salivary 17b-estradiol level
(P ¼ 0.31) or overall mean salivary progesterone level (P ¼ 0.91)
between nulliparous and parous women (Table II) or between
women who had given birth to one child compared with women
who had given birth to multiple children (results not presented in
table). We observed no difference in average daily level of salivary
17b-estradiol throughout the entire menstrual cycle among three
parity groups (nulliparous, 1–2 children, 3–5 children; P ¼ 0.57,
adjusted for age; Fig. 1A).
When subjects were stratiﬁed by BMI and parity, there was a differ-
ence in average salivary 17b-estradiol levels throughout the entire
Ovarian hormones, reproduction and breast cancer 1521menstrual cycle between the four groups of women (P ¼ 0.016,
age-adjusted): parous women with BMI ≥ 25 kg/m
2 had a higher
average daily level of salivary 17b-estradiol throughout the entire men-
strual cycle compared with both nulliparous women (P ¼ 0.021,
age-adjusted) and parous women (P ¼ 0.018, age-adjusted) with
BMI , 25 kg/m
2 (Fig. 1B). Also, nulliparous women with BMI ≥
25 kg/m
2 had a higher average daily level of salivary 17b-estradiol
throughout the entire menstrual cycle when compared with nullipar-
ous women with BMI , 25 kg/m
2 (P ¼ 0.039, age-adjusted). Nullipar-
ous women with WC ≥ 77.75 cm had higher average daily levels of
salivary 17b-estradiol throughout the entire menstrual cycle compared
with nulliparous women with lower WC (P ¼ 0.017, age-adjusted).
There was a tendency of higher average daily levels of salivary
17b-estradiol throughout the entire menstrual cycle also among
parous women with WC ≥ 77.75 compared with nulliparous
women with lower WC (P ¼ 0.068, age-adjusted; Fig. 1C).
Finally, when we stratiﬁed women by parity and OC use, we
observed no difference in average levels of salivary 17b-estradiol
between the four groups of women deﬁned by median split of the
two variables (P ¼ 0.19, age-adjusted). However, in subgroup analysis,
nulliparous women with ≥3 years of OC use had higher average daily
levels of salivary 17b-estradiol throughout the entire menstrual cycle
compared with nulliparous women with fewer years of OC use
(P ¼ 0.050, age-adjusted; Fig. 1D).
In an analysis using AUC, women with three to ﬁve full-term preg-
nancies had a tendency of higher 17b-estradiol values for the mid-
menstrual cycle and mid-cycle intervals, compared with nulliparous
women and women with less than two full-term pregnancies
.................................. ..................................
.............................................................................................................................................................................................
Table I Characteristics of the study population according to parity. The Norwegian EBBA-I study (n 5 204)
a.
Characteristic Parous (n 5 98
a) Nulliparous (n 5 106
a) P-value
b
Mean (SD) Mean (SD)
Age, years 32.4 (2.56) 29.2 (2.71) ,0.001
Education, total years 15.1 (3.09) 17.0 (2.63) ,0.001
Partnership, total years 8.16 (5.49) 2.95 (3.69) ,0.001
Body composition
c
Height, cm 167.1 (6.51) 166.6 (6.51) 0.58
BMI, kg/m
2 25.1 (3.83) 23.7 (3.58) 0.010
WC, cm 81.9 (10.1) 77.3 (8.97) 0.001
Waist to hip ratio 0.79 (0.06) 0.76 (0.06) ,0.001
Serum lipids, fasting
Total cholesterol, mmol/l 4.51 (0.79) 4.39 (0.77) 0.25
HDL cholesterol, mmol/l 1.49 (0.34) 1.58 (0.32) 0.049
Triglycerides, mmol/l 0.87 (1.08) 0.87 (1.01) 0.99
Clinical measurements
Systolic blood pressure (mmHg) 113.3 (12.1) 113.3 (10.3) 0.99
Diastolic blood pressure (mmHg) 71.0 (8.24) 70.8 (7.83) 0.87
Reproductive history
Age at Menarche, years 13.1 (1.42) 13.2 (1.32) 0.67
Cycle length, days 27.8 (2.96) 28.6 (3.31) 0.61
Number of children 1.88 (0.88)
Previous use of oral contraceptives, years 4.44 (3.85) 3.24 (3.46) 0.020
Time since last use of oral contraceptives, years 7.13 (4.47) 3.84 (3.47) ,0.001
Energy intake, kJ/day 8007 (1991) 8173 (1917) 0.53
Alcohol, units/week 2.85 (1.10) 3.56 (1.24) ,0.001
Current smokers,% 26.5 17.9 0.14
Physical activity in leisure time,%
Sedentary activity 13.3 17.9 0.20
Moderate activity 64.3 54.7
Regular activity 22.4 27.4
Values are means (standard deviation, SD) and percents.
WC, waist circumference.
aNumbers may vary due to missing information.
bStudent’s t-test or x
2 test.
cMeasurements at Day 1–5 after onset of menstrual cycle.
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Table II Salivary ovarian hormone concentrations (age-adjusted geometric means, 95% CI) among parous and
nulliparous women. The Norwegian EBBA-I study (n 5 204)
a.
Ovarian steroids Parous (n 5 98
a) Nulliparous (n 5 106
a) P-value
b
Mean 95% CI Mean 95% CI
17b-estradiol, pmol/l
Overall 17b-estradiol 14.6 (13.0,16.4) 13.4 (12.0,14.9) 0.31
Mid-follicular 17b-estradiol
c 11.3 (9.53,13.3) 9.69 (8.27,11.4) 0.23
Late follicular 17b-estradiol
d 17.3 (15.2,19.7) 17.5 (15.5,19.8) 0.91
Overall Progesterone, pmol/l 94.2 (80.9,109.8) 95.6 (82.1,111.2) 0.91
CI, conﬁdence interval.
aNumber may vary due to missing information.
bLinear regression with log transformed hormones as dependent variable.
cAligned cycle Day 210, 26.
dAligned cycle Day 25,21.
Figure 1 Daily salivary 17b-estradiol concentrations (geometric means) in mid-menstrual cycle for women categorized by (A) number of children;
nulliparous (n ¼ 99), 1–2 children (n ¼ 74), 3–5 children (n ¼ 17), (B) BMI; nulliparous and BMI ,25 kg/m
2 (n ¼ 70), nulliparous and BMI ≥25 kg/
m
2 (n ¼ 29), parous and BMI ,25 kg/m
2 (n ¼ 54), parous and BMI ≥25 kg/m
2 (n ¼ 37), (C) WC (median split); nulliparous and waist circumference
,77.75 cm (n ¼ 61), nulliparous and waist circumference ≥77.75 cm (n ¼ 38), parous and waist circumference ,77.75 cm (n ¼ 36), parous and
waist circumference ≥77.75 cm (n ¼ 55), (D) OC use (median split); nulliparous and OC ,3 years total use (n ¼ 55), nulliparous and OC ≥3
years total use (n ¼ 44), parous and OC ,3 years total use (n ¼ 39), parous and OC ≥3 years total use (n ¼ 52).
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gesterone values compared with all other women in the study, but the
association was not statistically signiﬁcant.
‘Menarche-to-ﬁrst birth’ interval and
hormonal levels
A shorter interval between menarche and ﬁrst full-term pregnancy
was associated with later age at menarche (Ptrend ¼ 0.010), younger
age at ﬁrst and last full-term pregnancy (both: Ptrend , 0.001),
higher parity (Ptrend ¼ 0.002), longer time since last birth (Ptrend ,
0.001) and fewer years of education (Ptrend ¼ 0.001) (Table IV).
Overall mean salivary level of 17b-estradiol was inversely related to
the length of the time interval between menarche and ﬁrst birth
(Ptrend ¼ 0.029, age-adjusted, Table V). Overall mean salivary pro-
gesterone level was not related to the length of the ‘menarche-
to-ﬁrst birth’ interval (Ptrend ¼ 0.34, age adjusted). The inverse
relationship between ‘menarche-to-ﬁrst birth’ interval and
17b-estradiol was observed across different weight categories (BMI
cut-off for overweight, 25 kg/m
2), age groups (median split, 33
years) and age at menarche (median split, 13.0 years) (data not
shown). The age-adjusted geometric mean for maximum peak salivary
17b-estradiol level was 33.0 pmol/l (95% CI, 27.3–39.9) in the lower
tertile of ‘menarche-to-ﬁrst birth’ interval, 27.2 pmol/l (95% CI, 24.4–
30.4) in the mid tertile and 22.5 pmol/l (95% CI, 19.0–26.6) in the
upper tertile, equaling a 47% higher maximum peak level of
17b-estradiol for women with the shortest ‘menarche-to-ﬁrst birth’
interval when compared with women with the longest interval (data
not shown in tables).
When analyzing the ‘menarche-to-ﬁrst birth’ interval as a continu-
ous predictor variable in age- and BMI-adjusted linear regression
models, we observed a 2.6% (P ¼ 0.039) decrease in overall
average salivary 17b-estradiol with each 1-year increase in the interval
(results not shown). We examined the mean salivary 17b-estradiol
concentrations by cycle day and observed a difference among the
three ‘menarche-to-ﬁrst birth’ interval groups (lower tertile: ,10
years; middle tertile: 10–13.5 years; upper tertile: .13.5 years; P ¼
0.010, age-adjusted; Fig. 2).
In analysis of AUC, women with the shortest time interval between
menarche and ﬁrst birth (,10 years) had  30% higher mid-cycle
17b-estradiol levels (Ptrend ¼ 0.050, age-adjusted) compared with
women with the longest intervals (.13.5 years) (Table VI). There
was no difference in progesterone values between women in different
‘menarche-to-ﬁrst birth’ tertiles (Ptrend ¼ 0.99, age-adjusted).
Discussion
In our study of full cycle proﬁles of free 17b-estradiol and progester-
one among healthy regularly cycling women, we observed no overall
association with parity. Interestingly, however, larger waist and longer-
term use of OCs were associated with higher daily levels of
17b-estradiol throughout the entire menstrual cycle among nullipar-
ous women. Furthermore, a strong inverse association between the
time interval from menarche to ﬁrst full-term birth and daily salivary
17b-estradiol levels over an entire menstrual cycle among young
healthy women with regular menstrual cycles was observed.
Women with the shortest ‘menarche-to-ﬁrst birth’ interval had 47%
higher maximum peak level and 30% higher mid-cycle 17b-estradiol
levels compared with the women with the longest interval.
Several previous studies have documented that positive energy
balance (Furberg et al., 2005), low physical activity (Verkasalo et al.,
2001; Jasienska et al., 2006c; Tworoger et al., 2007) and higher
energy resources (Ziomkiewicz et al., 2008) have a positive effect
on levels of reproductive ovarian steroids, which in turn improve
chances for conception (Lipson and Ellison, 1996; Venners et al.,
2006). There are however very limited data on the association
....................................................................................................................................
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Table III Estimated cumulative load of salivary ovarian steroids during menstrual cycle according to parity. The
Norwegian EBBA-I study (n 5 189)
a.
Ovarian steroids Number of children P-trend
c
0( n 5 99) 1 (n 5 36) 2 (n 5 37) 3–5 (n 5 17)
Mean
b (95% CI) Mean
b (95% CI) Mean
b (95% CI) Mean
b (95% CI)
17b-estradiol pmol/l
Mid-menstrual
d, 14 days 213 (192,236) 220 (205,236) 228 (202,257) 236 (195,286) 0.41
Mid-cycle
e, 6 days 108 (97,120) 112 (104,121) 116 (102,130) 120 (98,145) 0.43
Late follicular
f, 5 days 74 (63,93) 75 (69,81) 76 (67,86) 76 (63,93) 0.79
Progesterone, pmol/l
Luteal
g, 8 days 969 (866,1083) 934 (860,1013) 900 (789,1026) 867 (703,1070) 0.42
Values are area under curve (AUC, pmol/l).
CI, conﬁdence interval.
aNumber may vary due to missing information.
bAge-adjusted geometric mean.
cLinear regression with log transformed hormones as dependent variable.
dAligned cycle Day 27,+6.
eAligned cycle Day 24,+2.
fAligned cycle Day 25,21.
gAligned cycle Day +2,+9.
1524 Iversen et al.between parity and ovarian hormone levels. The present observation
supporting no overall associations between levels of 17b-estradiol and
progesterone with parity is in agreement with those of former studies
(Verkasalo et al., 2001) and importantly, this may lead to further ques-
tions related to interacting predisposition and the need of more
detailed studies.
Interestingly, nulliparous women with larger waist circumference
had higher salivary 17b-estradiol levels compared with nulliparous
women with a more narrow waist circumference, supporting that nul-
liparous women may be more susceptible to lifestyle factors inﬂuen-
cing energy balance, abdominal overweight, and metabolic and
hormonal proﬁles. Correspondingly, a positive linear relationship
between body fat and estradiol levels throughout an entire menstrual
cycle was observed in a parallel study among premenopausal Polish
women (Ziomkiewicz et al., 2008). Furthermore, regulation of
ovarian hormone levels by nutritional status has been suggested, for
example, in studies of women with anorexia nervosa (Miller et al.,
2004), and in studies of women in rural communities with seasonal
variation in workload (Panter-Brick et al., 1993). Accumulation of
excessive abdominal fat is related to insulin resistance with hyperinsu-
linemia. Insulin stimulates ovarian steroidogenesis and inhibits the
hepatic synthesis of SHBG, leading to increased levels of free estradiol
(Verkasalo et al., 2001; IARC, 2002; Finstad et al., 2009b). This may
explain the positive relation between waist circumference and free
17b-estradiol levels seen in our study, contrary to other studies that
have reported inverse associations between waist circumference and
total estradiol and its main binding protein, SHBG. However, adjust-
ment for serum SHBG measured at the ﬁrst visit did not change our
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Table IV Characteristics of the study population according to length of the ‘menarche-to-ﬁrst birth’ interval (tertiles).
The Norwegian EBBA-study (n 5 98)
a.
Characteristic Interval between menarche and age at ﬁrst birth, years P- trend
b
<10 years (n 5 30) 10–13.5 years
(n 5 35)
>13.5 years
(n 5 33)
Mean (SD) Mean (SD) Mean (SD)
Age, years 32.0 (3.10) 32.0 (2.54) 33.0 (1.90) 0.12
Education, total years 13.3 (2.93) 15.6 (2.33) 16.0 (2.30) 0.001
Partnership, total years 9.54 (6.78) 7.35 (5.10) 7.80 (4.51) 0.26
Body composition
c
Height, cm 165.9 (5.26) 169.5 (6.96) 165.8 (6.37) 0.76
BMI, kg/m
2 24.8 (3.31) 25.1 (4.10) 25.2 (4.04) 0.77
WC, cm 81.4 (8.11) 83.0 (10.90) 81.2 (11.15) 0.94
Waist to hip ratio 0.80 (0.06) 0.79 (0.06) 0.77 (0.07) 0.07
Reproductive history
Age at Menarche, years 13.4 (1.22) 13.3 (1.27) 12.5 (1.61) 0.010
Cycle length, days 27.5 (3.00) 28.0 (3.38) 27.8 (2.48) 0.62
Number of children 2.30 (0.95) 1.80 (0.90) 1.61 (0.66) 0.002
Age at ﬁrst birth, years 20.1 (2.05) 24.8 (1.71) 28.2 (2.26) ,0.001
Age at last birth, years 25.6 (3.29) 27.4 (2.96) 29.7 (2.35) ,0.001
Time since last birth, years 6.41 (3.37) 4.61 (3.12) 3.31 (1.76) ,0.001
Total breastfeeding, months 21.3 (12.76) 17.8 (14.73) 18.9 (9.27) 0.46
Previous use of oral contraceptives, years 4.00 (3.71) 4.71 (3.77) 4.56 (4.13) 0.58
Time since last use of oral contraceptives, years 7.58 (5.42) 7.10 (4.13) 6.71 (3.86) 0.47
Energy intake, kJ/day 7866 (1760) 8145 (2131) 7988 (2084) 0.82
Alcohol, units/week 2.67 (1.01) 3.08 (1.28) 2.77 (0.91) 0.76
Current smokers,% 43.3 20.0 18.2 0.043
Physical activity in leisure time,%
Sedentary 20.0 8.60 12.1 0.95
Moderate 53.3 74.3 63.6
Regular 27.7 17.1 24.3
Values are means (standard deviation, SD) and percents.
WC, waist circumference.
aNumber may vary due to missing information.
bLinear regression or logistic regression.
cMeasurements at Day 1–5 after onset of menstrual cycle.
Ovarian hormones, reproduction and breast cancer 1525estimates (analysis not presented). In addition, obesity may lead to
anovulatory cycles and increased conversion of androgens to
estrone in adipose tissue, while the EBBA women were mostly non-
obese with normal levels of serum lipids (Furberg et al., 2005). There-
fore, our ﬁndings support that long-term positive energy balance
reﬂected by larger waist circumference may increase level of free
17b-estradiol in women with regular ovulations, particularly in nulli-
parous women.
In our study, longer-term use of OCs was associated with higher
levels of 17b-estradiol throughout the entire menstrual cycle among
nulliparous women. Current use of OCs inﬂuences endogenous sex
hormone levels, while the association between former use of OCs
and circulating levels of 17b-estradiol in adult women is poorly docu-
mented. Our ﬁndings suggest that the ovarian function in nulliparous
women may be more susceptible to long-term suppression by
exogenous hormones and possible boosting of 17b-estradiol pro-
duction after cessation of the pill—we hypothesize that OC exposure
may change the physiological set point for the regulation of endogen-
ous hormone levels especially among women that have not experi-
enced a full-term pregnancy. Prospective studies are needed to
determine the stability of the hypothalamic–pituitary–ovarian axis
phenotype. It might also be that OC use itself is a behavior partially
determined by endogenous hormone levels or hormone-related
factors.
The present observations that parous women with shorter
‘menarche-to-ﬁrst birth’ intervals had a higher parity, lower age at
ﬁrst birth, and higher salivary 17b-estradiol levels than women with
longer intervals are indirectly supported by others. Associations
between early age at menarche and higher estradiol levels (Bernstein
et al., 1991; Emaus et al., 2008a), and higher frequencies of ovulation
(Apter et al., 1989) have been observed. Higher energy resources
associated with higher estrogens within normal range improve
chances for conception (Lipson and Ellison, 1996; Venners et al.,
2006). Higher follicular levels of estradiol have been observed in
healthy women’s menstrual cycles resulting in conception, compared
with cycles without conception (Lipson and Ellison, 1996; Venners
et al., 2006). Furthermore, the pattern of human sexual behavior is
complex but may be explained partly by estradiol levels (Pawlowski
and Jasienska, 2005; Durante and Li, 2009). An elevated level of estra-
diol may lead to more frequent sexual activity, thereby increasing the
likelihood of fertilization and parity (Durante and Li, 2009). In the
EBBA women, early age at ﬁrst birth is the main determinant of a
shorter menarche-to-ﬁrst-birth interval rather than late age at
menarche—this could be the consequence of conscious choice or a
consequence of higher fecundity, or both. On the basis of our obser-
vations, we hypothesize that childbearing pattern (i.e. delayed child-
births) in this female population is partly determined by variation in
fecundity which again is partly determined by genetic variation in pro-
teins regulating ovarian function as well as gene–environment (i.e.
socio-cultural) interactions. Further studies are needed to explore
this hypothesis.
Several studies have documented an increase in risk of breast
cancer with elevated serum estradiol levels in post-menopausal
Figure 2 Daily salivary 17b-estradiol concentrations (geometric
means) in mid-menstrual cycle for women categorized by tertiles of
interval length from menarche to age at ﬁrst full term birth. Lower
tertile; interval ,10 years (n ¼ 26). Middle tertile; interval 10–13.5
years (n ¼ 32). Upper tertile; interval .13.5 years (n ¼ 33).
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Table V Salivary ovarian hormone concentrations (age-adjusted geometric means, 95% CI) among women in groups of
‘menarche-to-ﬁrst birth’ interval (tertiles). The Norwegian EBBA-I study (n 5 98)
a.
Ovarian steroids Interval between menarche and age at ﬁrst birth, years P-trend
b
<10 years (n 5 30) 10–13.5 years (n 5 35) >13.5 years (n 5 33)
Mean (95% CI) Mean (95% CI) Mean (95% CI)
17b-estradiol, pmol/l
Overall 17b-estradiol 16.2 (13.8,19.3) 14.1 (12.7,15.6) 12.2 (10.4,14.3) 0.029
Mid-follicular 17b-estradiol
c 11.0 (8.68,14.0) 10.3 (8.98,11.8) 9.63 (7.67,12.1) 0.47
Late follicular 17b-estradiol
d 18.7 (15.2,23.0) 16.8 (15.0,18.9) 15.1 (12.7,18.1) 0.17
Overall Progesterone, pmol/l 99.2 (77.9,126.3) 90.6 (78.7,104.3) 82.8 (65.9,103.9) 0.34
CI, conﬁdence interval.
aNumber may vary due to missing information.
bLinear regression with log transformed hormones as dependent variable.
cAligned cycle Day 210, 26.
dAligned cycle Day 25, 21.
1526 Iversen et al.women (Endogenous Hormones and Breast Cancer Collaborative
Group, 2002; Prentice et al., 2008). There is evidence for a similar
relationship also in premenopausal women (Eliassen et al., 2006)
even though the ﬂuctuating level of hormones during the menstrual
cycle complicates testing of the hypothesis in premenopausal
women (Kaaks et al., 2005).
Our observations suggest that nulliparity in combination with pre-
vious OC use and positive energy balance increases the 17b-estradiol
levels associated with increased breast cancer risk. Greater BMI and
obesity are associated with decreased breast cancer risk in studies
of premenopausal women (Friedenreich, 2001; Berstad et al., 2010)
while both current and former OC users have an increased risk of
breast cancer in recent studies (Lund et al., 2007; Hunter et al.,
2010). Low parity is a well-established risk factor for breast cancer
(MacMahon et al., 1970; Braaten et al., 2004; World Cancer Research
Fund/American Institute for Cancer Research, 2007). A few studies
have suggested that giving birth before age 20 is associated with
lower risk of breast cancer (MacMahon et al., 1970), whereas ﬁrst
birth at ages above 35 increases breast cancer risk (Trichopoulos
et al., 1983), possibly due to increased likelihood of malignant trans-
formations in breast cancer cells in older women. In general,
massive differentiation of epithelial breast cells in response to the
increased release of ovarian hormones during pregnancy has been
proposed as an explanation for both the elevated short-term breast
cancer risk after pregnancy, and the extended protective effect of
pregnancy (Lambe et al., 1994; Albrektsen et al., 2010).
Furthermore, the longer period of time during which immature
breast epithelium cells are exposed to estradiol may cause an elevated
risk (Russo et al., 1982; Pike et al., 1993) pointing to the interval
between age at menarche and age at ﬁrst birth, relevant for breast
cancer risk (Li et al., 2008; McDougall et al., 2010), and
estradiol-receptor-positive tumors in particular (Li et al., 2008). A
strong inverse association between the time interval ‘menarche-
to-ﬁrst birth’ and levels of these hormones suggests that there may
be biological mechanisms other than the ovarian steroid pathway
that underlie the associations between parity, age at ﬁrst birth and
breast cancer risk. A recent study suggested that a single full term
pregnancy decreased the levels of circulating growth hormones
(GH), shown to play a role in breast carcinogenesis with insulin-like
growth factor I (IGF-I), thus pointing at another potential biological
mechanism for protection from breast cancer (Dearth et al., 2010).
Further studies are required to fully understand the mechanisms
underlying the association between reproductive history and risk of
breast cancer.
Our study has the beneﬁt of having collected samples every day
over an entire menstrual cycle, rather than only on selected days
within a cycle. This allows for estimation of daily free, unbound
and biologically active 17b-estradiol and progesterone, and for high
quality estimates of full cycle ovarian hormone proﬁles (Jasisenska
and Jasienski, 2008). Furthermore, well-developed and validated
methods and assays were used to characterize the women’s
exposure to free biologically active ovarian steroids and compare
levels by aligned cycle days (Lipson and Ellison, 1996). In addition,
salivary levels of 17b-estradiol were shown to be quite stable
within participants over time (Ellison and Lipson, 1999). Salivary
estradiol represents about 1% of the total circulating estradiol, and
therefore the absolute values are small in comparison to the
serum estradiol levels used in clinical practice. The salivary
17b-estradiol proﬁles for the EBBA women closely resemble the
well-known physiological pattern for cyclic variation in estradiol
(Speroff and Fritz, 2005), and large relative differences between indi-
viduals were observed (i.e. 47% higher maximum peak level of
17b-estradiol for women with the shortest ‘menarche-to-ﬁrst
birth’ interval as compared with women with the longest interval).
Furthermore, a study evaluating estradiol levels in daily saliva
samples for two consecutive menstrual cycles among 12 women
observed higher variance in mean estradiol levels between women
than between cycles from the same woman, suggesting that a
..........................................................................................................................
.................................. .................................. ..................................
.............................................................................................................................................................................................
Table VI Estimated cumulative load of salivary ovarian steroids during menstrual cycle according length of the
‘menarche-to-ﬁrst birth’ interval (tertiles). The Norwegian EBBA-I study (n 5 90)
a.
Ovarian steroids Interval between menarche and age at ﬁrst birth P-trend
c
<10 years (n 5 29) 10–13.5 years (n 5 31) >13.5 years (n 5 30)
Mean
b (95% CI) Mean
b (95% CI) Mean
b (95% CI)
17b-estradiol, pmol/l
Mid-menstrual
d, 14 days 241 (205,286) 218 (197,242) 197 (167,232) 0.11
Mid-cycle
e, 6 days 125 (106,148) 110 (99,122) 96 (82,114) 0.050
Late follicular
f, 5 days 80 (67,96) 72 (65,80) 65 (55,77) 0.12
Progesterone, pmol/l
Luteal
g, 8 days 857 (700,1049) 858 (757,971) 859 (703,1048) 0.99
Values are area under curve (AUC, pmol/l).
CI, conﬁdence interval.
aNumber may vary due to missing information.
bAge adjusted geometric mean.
cLinear regression with log transformed hormones as dependent variable.
dAligned cycle Day 27,+6.
eAligned cycle Day 24,+2.
fAligned cycle Day 25,21.
gAligned cycle Day +2,+9.
Ovarian hormones, reproduction and breast cancer 1527single menstrual cycle will give reliable estimates in the analysis of
interindividual differences (Gann et al., 2001).
The main independent variables in our study (i.e. age at menarche,
age at ﬁrst full-term birth and parity) represent reproductive life mile-
stones, and the women were 25–35 years at participation—these
aspects facilitate high reliability of the self-reported data. Furthermore,
to minimize false memory of exposures, each woman was interviewed
by a trained nurse actively using a detailed lifetime calendar and a list of
examples of milestones. In a previous study of the EBBA women, we
have shown that age at menarche is associated with 17b-estradiol
levels (Emaus et al., 2008a). Also, self-reported birthweight showed
to be nearly identical with the birthweight registered at the Medical
Birth Registry of Norway (Emaus, 2009).
Our results indicate that lifestyle factors including OC use, excess
weight and timing of ﬁrst birth are associated with ovarian steroid
levels among regularly cycling women. Interestingly, long-term positive
energy balance may increase 17b-estradiol levels in women with
regular ovulations, particularly in nulliparous women. Furthermore,
fecundity seems to play a signiﬁcant role in timing of ﬁrst childbirth.
These ﬁndings demonstrate the complexity of the relationships
among reproductive factors, levels of ovarian hormones, fecundity
and breast cancer risk.
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